Journal
Cancer Biotherapy & Radiopharmaceuticals
Publication Date
6-1-2022
Volume
37
Issue
5
First Page
355
Last Page
363
Document Type
Open Access Publication
DOI
10.1089/cbr.2022.0010
Rights and Permissions
Abou DS, Zerkel P, Robben J, McLaughlin M, Hazlehurst T, Morse D, Wadas TJ, Pandya DN, Oyama R, Gaehle G, Nickels ML, Thorek DLJ. Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies. Cancer Biother Radiopharm. 2022 Jun;37(5):355-363. doi: 10.1089/cbr.2022.0010 This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License [CC-BY-NC] ( http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited.
Recommended Citation
Abou, Diane S; Zerkel, Patrick; Robben, James; McLaughlin, Mark; Hazlehurst, Tim; Morse, David; Wadas, Thaddeus J; Pandya, Darpan N; Oyama, Reiko; Gaehle, Gregory; Nickels, Michael L; and Thorek, Daniel L J, "Radiopharmaceutical quality control considerations for accelerator-produced actinium therapies." Cancer Biotherapy & Radiopharmaceuticals. 37, 5. 355 - 363. (2022).
https://digitalcommons.wustl.edu/oa_4/333
Supplementary Figure S1
Suppl_FigureS2.docx (166 kB)
Supplementary Figure S2
Suppl_FigureS3.docx (163 kB)
Supplementary Figure S3
Suppl_FigureS4.docx (158 kB)
Supplementary Figure S4
Suppl_FigureS5.docx (252 kB)
Supplementary Figure S5
